EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations

Sherlot Juan Song, Eileen Laureal Yoon, Vincent Wai-Sun Wong, Ae Jeong Jo, Grace Lai-Hung Wong, Jimmy Che-To Lai, Dae Won Jun, Terry Cheuk-Fung Yip

Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 646-660

DOI: 10.3350/cmh.2025.0851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Sherlot Juan Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Bureau of HKSAR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Previous studies have identified a substantial degree of agreement between the non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) populations, but the same notion may not apply to normal-weight patients with a lower cardiometabolic risk burden. This study aims to investigate the cardiometabolic risk factor (CMRF) distributions between normal-weight and overweight/obese MASLD, the agreement between historical NAFLD and MASLD, and to compare the risk of liver-related events (LREs) and all-cause mortality in normal-weight versus overweight or obese MASLD.

Methods

This study included participants with steatotic liver disease (SLD) from five cohorts in China (Hong Kong), South Korea, and the United States. Participants were recruited from settings including both hospitals and communities. Individuals were classified into normal-weight and overweight/obese groups.

Results

This study included 33,793 participants with SLD from five cohorts, of whom 20,893 and 20,701 patients met the diagnosis of NAFLD and MASLD, respectively. Normal-weight patients with NAFLD demonstrated a lower CMRF distribution compared to those with overweight/obese NAFLD. In the community-based cohorts, the proportions with 0 CMRF ranged from 9.0 to 26.7% among normal-weight NAFLD patients, representing the discrepancy between MASLD and NAFLD definitions. Compared with the overweight/obese MASLD, the normalweight MASLD had increased all-cause mortality (normal-weight vs. overweight/obese, 23.44 and 13.80 per 1,000 person-years; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseFatty LiverHumansMaleFemaleMiddle AgedAdultObesityCohort StudiesOverweightBody Mass IndexRisk FactorsAgedUnited StatesBody WeightRepublic of Korea

Stichwörter der Autor:innen

Cardiometabolic risk factorsHepatic steatosisNonalcoholic fatty liver disease

Autor:innen und Institutionen

  • Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
  • Department of Information Statistics, Andong National University, Andong, Korea.

Förderung

  • Health Bureau of HKSAR

Zitieren

APA

Song, S. J., Yoon, E. L., Wong, V. W., Jo, A. J., Wong, G. L., Lai, J. C., Jun, D. W., & Yip, T. C. (2026). Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations. Clinical and Molecular Hepatology, 32(2), 646-660. https://doi.org/10.3350/cmh.2025.0851

Vancouver

Song SJ, Yoon EL, Wong VW, Jo AJ, Wong GL, Lai JC, et al. Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations. Clinical and Molecular Hepatology. 2026;32(2):646-660. doi:10.3350/cmh.2025.0851

BibTeX
@article{Song2026,
  author = {Song, Sherlot Juan and Yoon, Eileen Laureal and Wong, Vincent Wai-Sun and Jo, Ae Jeong and Wong, Grace Lai-Hung and Lai, Jimmy Che-To and Jun, Dae Won and Yip, Terry Cheuk-Fung},
  title = {Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {646--660},
  doi = {10.3350/cmh.2025.0851}
}
Kostenlos starten →